Video

Studies in chronic lymphocytic leukemia (CLL) treatment in frontline and relapsed/refractory settings, presented at the American Society of Hematology (ASH) 2024 Annual Meeting and Exposition, are discussed by Dr Muhammad Jawad Javed of Albany Medical Center and Stratton VA.

Dr Javed begins with the AMPLIFY trial, the first phase 3 study to evaluate a fixed-duration regimen of venetoclax with a second-generation BTK inhibitor. AMPLIFY compares three frontline treatment arms: (1) acalabrutinib plus venetoclax (AV); (2) acalabrutinib plus venetoclax plus obinutuzumab (AVO); and (3) chemoimmunotherapy. Results showed improved progression-free survival (PFS) and overall survival (OS) in the AV and AVO groups.

The next frontline treatment study he discusses examined use of minimal residual disease testing to guide treatment duration of a venetoclax/obinutuzumab regimen. The study found that shorter treatment duration led to PFS comparable to that achieved by longer duration.

Dr Javed next turns to a retrospective analysis of the impact of first-line treatment choice on the risk for other malignancies, using data from the Department of US Veteran Affairs Central Cancer Registry.

In relapsed/refractory disease, Dr Javed highlights the BRUIN CLL-321 study of the noncovalent reversible BTK inhibitor pirtobrutinib. Pirtobrutinib improved PFS compared with chemoimmunotherapy.

Last, he discusses epcoritamab, which yielded encouraging complete response data in heavily pretreated CLL patients.

--

Muhammad Jawad Javed, MBBS, Albany Medical Center/Stratton VA Albany, Department of Medicine; Resident Physician, Department of Internal Medicine, Albany Medical Center, Albany, New York

Muhammad Jawad Javed, MBBS, has disclosed no relevant financial relationships

Studies in chronic lymphocytic leukemia (CLL) treatment in frontline and relapsed/refractory settings, presented at the American Society of Hematology (ASH) 2024 Annual Meeting and Exposition, are discussed by Dr Muhammad Jawad Javed of Albany Medical Center and Stratton VA.

Dr Javed begins with the AMPLIFY trial, the first phase 3 study to evaluate a fixed-duration regimen of venetoclax with a second-generation BTK inhibitor. AMPLIFY compares three frontline treatment arms: (1) acalabrutinib plus venetoclax (AV); (2) acalabrutinib plus venetoclax plus obinutuzumab (AVO); and (3) chemoimmunotherapy. Results showed improved progression-free survival (PFS) and overall survival (OS) in the AV and AVO groups.

The next frontline treatment study he discusses examined use of minimal residual disease testing to guide treatment duration of a venetoclax/obinutuzumab regimen. The study found that shorter treatment duration led to PFS comparable to that achieved by longer duration.

Dr Javed next turns to a retrospective analysis of the impact of first-line treatment choice on the risk for other malignancies, using data from the Department of US Veteran Affairs Central Cancer Registry.

In relapsed/refractory disease, Dr Javed highlights the BRUIN CLL-321 study of the noncovalent reversible BTK inhibitor pirtobrutinib. Pirtobrutinib improved PFS compared with chemoimmunotherapy.

Last, he discusses epcoritamab, which yielded encouraging complete response data in heavily pretreated CLL patients.

--

Muhammad Jawad Javed, MBBS, Albany Medical Center/Stratton VA Albany, Department of Medicine; Resident Physician, Department of Internal Medicine, Albany Medical Center, Albany, New York

Muhammad Jawad Javed, MBBS, has disclosed no relevant financial relationships

Studies in chronic lymphocytic leukemia (CLL) treatment in frontline and relapsed/refractory settings, presented at the American Society of Hematology (ASH) 2024 Annual Meeting and Exposition, are discussed by Dr Muhammad Jawad Javed of Albany Medical Center and Stratton VA.

Dr Javed begins with the AMPLIFY trial, the first phase 3 study to evaluate a fixed-duration regimen of venetoclax with a second-generation BTK inhibitor. AMPLIFY compares three frontline treatment arms: (1) acalabrutinib plus venetoclax (AV); (2) acalabrutinib plus venetoclax plus obinutuzumab (AVO); and (3) chemoimmunotherapy. Results showed improved progression-free survival (PFS) and overall survival (OS) in the AV and AVO groups.

The next frontline treatment study he discusses examined use of minimal residual disease testing to guide treatment duration of a venetoclax/obinutuzumab regimen. The study found that shorter treatment duration led to PFS comparable to that achieved by longer duration.

Dr Javed next turns to a retrospective analysis of the impact of first-line treatment choice on the risk for other malignancies, using data from the Department of US Veteran Affairs Central Cancer Registry.

In relapsed/refractory disease, Dr Javed highlights the BRUIN CLL-321 study of the noncovalent reversible BTK inhibitor pirtobrutinib. Pirtobrutinib improved PFS compared with chemoimmunotherapy.

Last, he discusses epcoritamab, which yielded encouraging complete response data in heavily pretreated CLL patients.

--

Muhammad Jawad Javed, MBBS, Albany Medical Center/Stratton VA Albany, Department of Medicine; Resident Physician, Department of Internal Medicine, Albany Medical Center, Albany, New York

Muhammad Jawad Javed, MBBS, has disclosed no relevant financial relationships